Breaking out of the investor gloom
This article was originally published in Clinica
Medtech companies should brace themselves for rough terrain ahead, as continued weakness in the economy and investor uncertainty spell a gloomy outlook. But planning for the long-term, among other safety measures, should enable your business to get through the hard times. Tina Tan finds out more at the MedTech Investing Europe conference
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.